{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:49:11Z","timestamp":1790801351748,"version":"4.1.0"},"reference-count":61,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Glucagon-like Peptide 1 (GLP-1)-based medications have been extensively studied for the management of type 2 diabetes, obesity, chronic kidney disease, and atherosclerotic cardiovascular disease. More recently, their potential role in preventing and treating heart failure has gained increasing attention. Given the strong pathophysiological links among diabetes, obesity, and heart failure, GLP-1-based medications represent a promising therapeutic option to improve morbidity and mortality across these interconnected conditions. In this review, we summarise and discuss recent studies involving GLP-1-based medications that have reported on HF-related outcomes. There is increasing evidence that these medications have beneficial effects on HF outcomes in patients with heart failure with preserved ejection fraction and possibly in those with mildly reduced ejection fraction. The usefulness of GLP-1-based medications in reduced ejection fraction HF remains to be defined.<\/jats:p>","DOI":"10.3390\/medicina62050870","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:27Z","timestamp":1777630527000},"page":"870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5581-8766","authenticated-orcid":false,"given":"Rachel Su Min","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jas-mine","family":"Seah","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baqar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-3137","authenticated-orcid":false,"given":"Piyush M.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Department of Cardiology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Advara Heart Care, Mulgrave Private Hospital, Mulgrave, Melbourne, VIC 3170, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-7102","authenticated-orcid":false,"given":"Eylem","family":"Levelt","sequence":"additional","affiliation":[{"name":"Department of Cardiometabolic Imaging, Baker Heart and Diabetes Institute, University of Melbourne, Melbourne, VIC 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-1602","authenticated-orcid":false,"given":"Angeline S.","family":"Leet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Vincent\u2019s Hospital Melbourne, Fitzroy, Melbourne, VIC 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I.","family":"MacIsaac","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Vincent\u2019s Hospital Melbourne, Fitzroy, Melbourne, VIC 3065, Australia"},{"name":"Department of Medicine, St Vincent\u2019s Hospital Melbourne, University of Melbourne, Fitzroy, Melbourne, VIC 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif I.","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Melbourne, VIC 3084, Australia"},{"name":"Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-6977","authenticated-orcid":false,"given":"Richard J.","family":"MacIsaac","sequence":"additional","affiliation":[{"name":"Department of Medicine, St Vincent\u2019s Hospital Melbourne, University of Melbourne, Fitzroy, Melbourne, VIC 3065, Australia"},{"name":"Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Melbourne, VIC 3052, Australia"},{"name":"Department of Endocrinology & Diabetes, St Vincent\u2019s Hospital Melbourne, Fitzroy, Melbourne, VIC 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.15420\/cfr.2024.06","article-title":"Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action","volume":"10","author":"Bykova","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2014","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral Semaglutide and Heart Failure Outcomes in Persons with Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial","volume":"186","author":"Rasmussen","year":"2026","journal-title":"JAMA Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tetaj, N., Segreti, A., Ferro, A., Ligorio, V., Spagnolo, A., and Grigioni, F. (2026). High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era. Genes, 17.","DOI":"10.3390\/genes17040370"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113116","DOI":"10.1016\/j.diabres.2026.113116","article-title":"Heart failure with preserved ejection fraction (HFpEF): Translational mechanisms, diagnostic evolution and therapeutic frontiers","volume":"232","author":"Gao","year":"2026","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., and Deng, X. (2026). GLP-1R agonists and heart failure: Novel beneficial effects suggested by Mendelian randomization. Eur. Heart J., ehaf1066.","DOI":"10.1093\/eurheartj\/ehaf1066"},{"key":"ref_9","first-page":"21","article-title":"SGLT2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Trials and Observational Studies: SGLT2 Inhibitors in Heart Failure","volume":"4","author":"Polat","year":"2026","journal-title":"J. Eur. Intern. Med. Prof."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.125.075157","article-title":"Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients with Type 2 Diabetes: A Target Trial Emulation","volume":"153","author":"Xu","year":"2026","journal-title":"Circulation"},{"key":"ref_11","unstructured":"European Medicines Agency (2026, February 09). Outcome of Assessment on Use of Mounjaro in Treatment of Heart Failure with Preserved Ejection Fraction in Adults with Obesity. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-outcome-assessment-use-mounjaro-treatment-heart-failure-preserved-ejection-fraction-adults-obesity_en.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"101","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"54","author":"Marso","year":"2016","journal-title":"Drug Ther. Bull."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70043","DOI":"10.1111\/obr.70043","article-title":"GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials","volume":"27","author":"Neves","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1111\/dom.16512","article-title":"Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Costa","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of Liraglutide on Clinical Stability Among Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102573","DOI":"10.1016\/j.jchf.2025.102573","article-title":"Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients with Heart Failure with Reduced Ejection Fraction and Implantable Cardiac Devices","volume":"13","author":"Marques","year":"2025","journal-title":"JACC Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ejhf.240","article-title":"Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: Insights from the GISSI-HF and Val-HeFT trials","volume":"17","author":"Rossignol","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_34","unstructured":"U.S. Department of Health and Human Services F and D Administration (2026, January 15). Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry Draft Guidance, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jjcc.2021.05.003","article-title":"Potential pitfalls when interpreting plasma BNP levels in heart failure practice","volume":"78","author":"Nishikimi","year":"2021","journal-title":"J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program","volume":"84","author":"Petrie","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","article-title":"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis","volume":"357","author":"Avogaro","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2022.12.006","article-title":"Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"45","author":"Huixing","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: A potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"F1010","DOI":"10.1152\/ajprenal.00028.2019","article-title":"Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?","volume":"317","author":"Katsurada","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Micu, M.A., Cozac, D.A., and Scridon, A. (2025). miRNA-Orchestrated Fibroinflammatory Responses in Heart Failure with Preserved Ejection Fraction: Translational Opportunities for Precision Medicine. Diagnostics, 15.","DOI":"10.3390\/diagnostics15182286"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014The role of the GLP-1 receptor","volume":"179","author":"Keppeler","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Neumann, J., Hofmann, B., Dhein, S., and Gergs, U. (2023). Glucagon and Its Receptors in the Mammalian Heart. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612829"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101641","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Er\u017een, S., Tonin, G., Juri\u0161i\u0107 Er\u017een, D., and Klen, J. (2024). Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031517"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.15420\/cfr.2025.17","article-title":"Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates","volume":"11","author":"Abdelhamid","year":"2025","journal-title":"Card. Fail. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"16598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-Blocker Use with Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients with Heart Failure with a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jacc.2024.04.064","article-title":"Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients with Type 2 Diabetes","volume":"84","author":"Chowdhary","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy","volume":"85","author":"Kramer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Jalil, J.E., Gabrielli, L., Ocaranza, M.P., MacNab, P., Fern\u00e1ndez, R., Grassi, B., Jofr\u00e9, P., Verdejo, H., Acevedo, M., and Cordova, S. (2024). New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084407"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial Fat and the Risk of Heart Failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2015","journal-title":"Rev. Diabet. Stud."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","unstructured":"(2026, April 14). FDA Update: Finerenone Approved to Treat HF Patients with LVEF \u226540%-American College of Cardiology. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2025\/07\/15\/20\/01\/FDA-Update-Finerenone-Approved."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106615","DOI":"10.1016\/j.ejim.2025.106615","article-title":"Robustness of randomized controlled trial evidence for SGLT2 inhibitors in heart failure with preserved and mildly reduced ejection fraction","volume":"145","author":"Zuin","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja2.51101","article-title":"Hospital admissions for cardiovascular complications of people with or without diabetes, Victoria, 2004\u20132016","volume":"215","author":"Kiburg","year":"2021","journal-title":"Med. J. Aust."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:35:36Z","timestamp":1777631736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050870"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050870","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}